Listen
METVIXIA (methyl aminolevulinate), photodynamic therapy
DERMATOLOGY - New indication
Opinions on drugs -
Posted on
May 10 2017
Reason for request
Extension of inclusion
METVIXIA with daylight has no proven clinical advantage over METVIXIA with photodynamic therapy in the management of actinic keratosis of the face and scalp
- METVIXIA has marketing authorisation, in combination with daylight, in the treatment of thin or non-hyperkeratotic and non-pigmented actinic keratoses of the face and scalp.
- Two open-label studies have shown that METVIXIA with daylight is non-inferior to METVIXIA with photodynamic therapy (red light), in terms of complete response rate at 12 weeks.
- The clinical data suggest that using METVIXIA with daylight results in less pain than when it is used with conventional photodynamic therapy.
Clinical Benefit
| Moderate |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
